XML 18 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Current Assets:    
Cash and cash equivalents $ 174,559 $ 187,675
Marketable securities 0 284,255
Accounts receivable, net of reserves of $4,689 in 2018 and $4,576 in 2017 265,012 234,597
Inventories 176,487 164,318
Other current assets 123,774 101,140
Total current assets 739,832 971,985
Long-Term Assets:    
Property and equipment, net 394,021 379,096
Goodwill 195,974 199,873
Intangible assets, net 39,036 43,846
Other long-term assets 151,822 118,616
Total long-term assets 780,853 741,431
TOTAL ASSETS 1,520,685 1,713,416
Current Liabilities:    
Accounts payable 68,015 66,968
Accrued liabilities 228,380 253,418
Line of credit 437,000 655,000
Current portion of deferred revenue 40,921 29,181
Total current liabilities 774,316 1,004,567
Long-Term Liabilities:    
Deferred income tax liabilities 35,459 25,353
Long-term debt 603,130 606,075
Long-term deferred revenue, net of current portion 65,362 35,545
Other long-term liabilities 83,267 95,718
Total long-term liabilities 787,218 762,691
Total liabilities 1,561,534 1,767,258
Commitments and Contingencies (Note 14)
Stockholders’ Deficit:    
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 104,847 shares in 2018 and 104,275 shares in 2017; Outstanding: 86,642 shares in 2018 and 87,104 shares in 2017 10,485 10,428
Additional paid-in capital 1,109,157 1,073,931
Deferred stock units: Outstanding: 162 units in 2018 and 229 units in 2017 4,398 5,988
Retained earnings 989,039 803,545
Accumulated other comprehensive income (loss) (42,559) (36,470)
Treasury stock, at cost: 18,195 shares in 2018 and 17,171 shares in 2017 (2,111,647) (1,911,528)
Total IDEXX Laboratories, Inc. stockholders’ deficit (41,127) (54,106)
Noncontrolling interest 278 264
Total stockholders’ deficit (40,849) (53,842)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 1,520,685 $ 1,713,416